Increasing access to oncology services in emerging economies is creating new opportunities for the Cabozantinib Market. Improvements in diagnostic capabilities, specialist care, and pharmaceutical distribution can expand access to targeted cancer treatments. The Cabozantinib Market was valued at US$ 1.46 billion in 2025 and is expected to reach US$ 2.67 billion by 2034, registering a CAGR of...